Tomorrow will be results, that's it. This build up to every single meeting Avacta has is tedious and pointless.
The RNS says this:
Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.
So we could get something this week or next on cohort 1 of 2w dosing.
SMDC were supposed to be reviewing the data end of April will be interesting next week. Although it will just be a recommendation to up the dose and continue I'd imagine.